Mobilization of suitable amounts of PBSCs with granulocyte-CSF (G-CSF) can be difficult in children. We report the results of using plerixafor in pediatric patients who failed to mobilize progenitors with G-CSF-based regimens. Thirty-three patients, median age 9 years (range 1-18 years) and median weight 29 kg (range 10-85 kg) were enrolled into the study. After 4 days of G-CSF stimulation, the median CD34+ cell count in peripheral blood was 10.4 per μL (range 0.27-23.0 per μL). Plerixafor was administered subcutaneously (0.24 μg/kg in 30 patients and 0.3 μg/kg in 3 patients) 11-12 h before apheresis. At the time of apheresis, CD34+ cell counts increased to a median of 44.1 per μL (range 8.4-357.0 per μL), a median 4.4-fold increase. Two patients (6%) failed to mobilize. Thirty-one patients underwent apheresis and in 27 42 × 10 6 CD34+ cells per kg of body weight were collected after one procedure. In total, 31 of 33 patients mobilized successfully and the median number of cryopreserved CD34+ cells was 5.6 × 10 6 /kg body weight (2.7 × 10 6 -27.4 × 10 6 ). Twenty-four patients underwent transplantation. Engraftment was achieved in all but one patient, who died on day +9 after hematopoietic stem cell transplantation. The median time of neutrophil and platelet recovery was day +12 and +16, respectively. Our study confirms that plerixafor has impressive efficacy and very modest toxicity in children.
INTRODUCTION
High-dose chemotherapy followed by autologous granulocyte-CSF (G-CSF)-mobilized stem cell transplantation (aSCT) has become a standard therapeutic option for pediatric patients with a range of solid tumors. The number of progenitors transplanted, reflected by the dose of CD34+ cells, is one of the key factors for successful aSCT. A dose of 2 × 10 6 CD34+ cells per kg body weight is considered minimally safe for sustained multilineage engraftment, although 5 × 10 6 /kg body weight provides much faster recovery of neutrophils and especially platelets and is thus considered to be the optimal dose. Due to favorable engraftment kinetics and a less traumatic method of collection, G-CSFmobilized PBSCs have almost completely replaced bone marrow as the source of autologous transplants. 1 The efficiency of PBSC mobilization depends directly on the dose of G-CSF, increasing linearly in the range 1-10 μg/kg body weight per day, before plateauing. Dividing the daily dose into two fractions given at 12-h intervals slightly increases the number of mobilized progenitor cells. The success of harvesting is nicely predicted by the CD34+ cell content in peripheral blood before apheresis, with 20 CD34+ cells per μL allowing collection of a minimally safe dose of CD34+ cells in 2-3 procedures and 50+ CD34+ cells per μL predicting collection of an optimal amount in one or two procedures. However, mobilization and collection of suitable amounts of PBSCs with G-CSF, alone or in combination with chemotherapy can be difficult. The efficiency of mobilization can be significantly impaired by certain concomitant diseases, bone marrow involvement by tumor cells, number of cycles of previous myelotoxic chemotherapy and irradiation involving areas of bone with active hematopoiesis. 2, 3 Also, a considerable proportion of patients without obvious risk factors for poor mobilization and up to 20% of healthy donors fail to increase sufficiently the number of progenitors in response to G-CSF, being idiopathic 'poor mobilizers'. [4] [5] [6] Plerixafor is a small molecule inhibitor of the CXCR4 chemokine receptor and blocks binding to its ligand, stromal cell-derived factor-1 alpha (SDF-1α). Devine et al. 7 showed that a single subcutaneous dose of plerixafor led to a sixfold increase in circulating CD34+ cells in patients with non-Hodgkin's lymphoma and multiple myeloma. Fowler et al.
8 assessed the combination of plerixafor and G-CSF in patients in whom mobilization with G-CSF alone failed. This approach led to successful mobilization in 18 of 20 patients. Use of plerixafor alone or in combination with G-CSF for CD34+ cell mobilization in healthy donors is being actively investigated. Devine's group showed that plerixafor as a single mobilizing agent was effective in 92% of healthy donors. They also showed that despite the decreased number of CD34+ cells collected with plerixafor (compared with G-CSF mobilization), the times to engraftment and immunological reconstitution after SCT were comparable. 9 A large proportion of primitive CD34+ cells in grafts mobilized with plerixafor may be the explanation. 10 Interestingly, CD34+ cell numbers in the graft were increased after mobilization with plerixafor and G-CSF compared with G-CSF alone, but this did not led to an increase in GvHD incidence, possibly due to the high number of regulatory T cells. 10, 11 Most studies of plerixafor have been carried out in adults and only single cases and small series have been reported in children. [12] [13] [14] [15] [16] [17] However, children may be a more suitable population for enhancing mobilization. Indeed, apheresis is technically more sophisticated in low-weight children, with more pronounced citrate toxicity and lower flow rate, resulting in a greater number of procedures and frequent need to prime apheresis contours with packed RBCs. Here we report our results of PBSC mobilization with plerixafor in pediatric patients who failed to achieve optimal CD34+ cell counts in peripheral blood after conventional mobilization with G-CSF alone or G-CSF plus chemotherapy.
MATERIALS AND METHODS
According to our institutional protocol for hematopoietic stem cell mobilization, all patients scheduled for autologous PBSC transplantation were given G-CSF (10-20 μg/kg per day, subcutaneously), either alone in the steady state or after receiving disease-specific chemotherapy as required by the corresponding protocol. In 'steady state'-mobilized patients, CD34+ cells in peripheral blood were counted in samples taken 96 h after the first dose of G-CSF; in chemotherapy plus G-CSF-mobilized patients, CD34+ cells were typically counted when the absolute granulocyte count reached 1000-2000 per μL. CD34+ cell counts were performed using a FACScan flow cytometer (Beckman Coulter, Miami, FL, USA) using a commercially available kit. All flow cytometry analyses were performed in duplicate, and means were calculated. Achieving a CD34+ cell count of ⩾ 20 cells per μL was considered successful mobilization. Stem cell apheresis was performed via the central venous line using a COBE Spectra v. 6.1 (Caridian BCT, Denver, CO, USA) or Spectra Optia v. 9.0 (Terumo BCN, Denver, CO, USA) cell separator not earlier than 2-3 h after the last G-CSF dose. The duration of each cell collection procedure was 3-8 h (median 5 h). The minimum targeted dose of CD34+ cells was 2 × 10 6 cells per kg before cryopreservation. When a CD34+ count of ⩾ 20 cells per μL was not achieved, patients were additionally stimulated with plerixafor (0.24 mg/kg bodyweight, subcutaneously) 11-12 h before scheduled apheresis, with subsequent measurement of CD34+ cells on the day of apheresis. If a sufficient dose of CD34+ cells was not collected after the first apheresis procedure, plerixafor stimulation was repeated with the same dose. G-CSF was continued until the last day of apheresis. Our protocol was approved by the Institutional Review Board and local Ethics Committee and informed consent was obtained from all patients or their legal guardians before administration of plerixafor. Genzyme, and then Sanofi, provided plerixafor for compassionate use.
RESULTS
During the study period (January 2010 to March 2014) insufficient CD34+ cell mobilization after 4 days of G-CSF administration was observed in 33 pediatric patients, 12.8% of those who entered the mobilization stage of the therapeutic protocol. In all patients the starting G-CSF dose was 10 μg/kg, but in six cases doses were increased (to 15 μg/kg day in one patient, and 20 μg/kg day in five patients) during the last 1 or 2 days due to low CD34+ cell numbers after 4 days of mobilization. There were 13 patients with relapsed/refractory lymphoma (seven Hodgkin's and six nonHodgkin's), 12 with neuroblastoma, 3 with osteosarcoma, 2 with acute myeloid leukaemia in CR2, 2 with germ cell tumors and 1 with medulloblastoma. Median age was 9 years (range 1-18 years), median weight 29 kg (range 10-85 kg). After 4 days of G-CSF stimulation, the median CD34+ cell count in peripheral blood was 10. Only two patients (6%) failed to mobilize CD34+ cells after receiving plerixafor. They had 14.1 and 9.5 cells/μL, the increment was o 1.5-fold and they did not undergo apheresis. Four patients with suboptimal numbers of harvested CD34+ cells received a second plerixafor injection before the second apheresis procedure. These second injections proved to be less effective: the CD34+ cell count was higher before the first apheresis procedure (median 38. ) was higher than that on the second day (median 124.6 × 10 6 , range 28.5 × 10 6 -172.1 × 10 6 ). In total, 31 of 33 patients mobilized successfully and the median number of cryopreserved CD34+ cells was 5.6 × 10 6 per kg body weight (range 2.7 × 10 6 -27.4 × 10 6 per kg). In 17 patients (55%) collected CD34+ cell number was 45 × 10 6 per kg body weight, in 11(35%) patients 3.5-5 × 10 6 per kg of body weight and in 3 patients (10%) 2.7-3.5 × 10 6 per kg of body weight. At the time of writing, 24 of 31 successfully mobilized patients had undergone transplantation. Engraftment was achieved in all but one patient who died due to infection on day +9 after HSCT. The median time of neutrophil recovery was day +12 (range +9 to +25) and of platelet engraftment was day +16 (range +9 to +30). Toxicity with plerixafor was observed in eight patients (24%) and was mild: WHO grade 1/2 diarrhea in five patients; grade 2 nausea in one patient; grade 1 ossalgia in one patient; and urticaria in one patient.
DISCUSSION
A harvested product of high quality is a prerequisite for effective aSCT rescue. Low numbers and poor proliferative potential of grafted hematopoietic progenitors result in delayed engraftment, a higher incidence of infection and longer need for platelet transfusions, and dramatically increase the cost of the procedure. Thus, efforts to optimize graft quality are warranted. Until recently, the only option to obtain a graft of desired quality in poor mobilizers was to repeat mobilization after a certain interval of rest, often using a combined chemotherapy plus G-CSF approach. This approach is not universally effective, is toxic and expensive, and, importantly, does not allow accurate scheduling of apheresis. It is particularly unsuitable for children. Despite its relatively recent approval, plerixafor plus G-CSF has become the gold standard approach in patients who fail to mobilize appropriate numbers of progenitors with G-CSF, and its use in adults is supported by current guidelines. In children, experience with plerixafor is more modest; no large study has been published to date. However, the proportion of poor mobilizers in pediatric populations seems to be comparable to that in adults; thus, children may benefit from plerixafor as much as, or even more than, adult patients. In our study, 12.8% of pediatric patients with various malignant tumors proved to be poor mobilizers; that is, they failed to achieve the threshold of 20 CD34+ cells per mm 3 when mobilized with high-dose G-CSF alone or G-CSF plus chemotherapy. In these 33 poor mobilizers, plerixafor led to dramatic (median 4.4-fold) increase in the numbers of circulating CD34+ cells. Overall, 31 patients reached the target CD34+ cell level and underwent apheresis. In 27 of them one procedure was sufficient to obtain a graft with appropriate characteristics; only two failed to mobilize a suitable number of cells. Of the 24 patients who underwent transplantation, 23 engrafted, and the kinetics of engraftment were similar to those seen after transplantation in good mobilizers. This finding suggests that the number of CD34+ cells per kg body weight, which is a good surrogate marker for engraftment kinetics in patients mobilized with G-CSF, retains its prognostic value in poor mobilizers 'boosted' with plerixafor. Assessing the toxicity of plerixafor, we can conclude that it is perfectly safe and only diarrhea occurs more frequently compared with mobilization with G-CSF alone. According to McCullough et al., 18 rates of G-CSF side effects, which include muscle ache, headache, drowsiness, nausea and other flu-like symptoms, can reach 76%.
One of the major potential issues with use of mobilized peripheral blood progenitors as a graft source is contamination by tumor cells egressing from bone marrow simultaneously with hematopoietic progenitors, as the mechanisms of adhesion of tumor cells to the stromal microenvironment are similar to those of normal stem cells. Although one large meta-analysis found no differences in malignant contamination between apheresis products mobilized with chemotherapy plus G-CSF and those mobilized with G-CSF alone, 19 these data cannot be directly extrapolated to plerixafor plus G-CSF regimens, as the mechanism of disruption of the cell-stroma interaction is different with plerixafor. This issue should be studied further, and posttransplantation relapse rates should be analyzed.
In conclusion, our study confirms preliminary reports on the use of plerixafor in pediatric patients and suggests that it has impressive efficacy and very modest toxicity.
